RTRX: I'm still a skeptic :-). I asked Martin about using Tracleer when its generic. He said Actelion said it wouldn't work. Someone else pointed out that the selectivity may be a reason so now I'd ask why Gilead or GSK wouldn't try a combo with ambrisentan (letairis). The way I see it its too risky for the following reasons (not necessarily in order): 1) Competitive risk (Other ERA+ARB/ACEi) 2) From the presentation it seems that ARB/ACEi have an effect on proteinuria so there is a bar. 3) I couldn't find human data so there is still efficacy and safety risk. 4) Brief history of CEO instability (not that I thought Aslegee was the ideal person for their stage to begin with). 5) I wasn't too comfortable with finding out Martin was involved in their MD molecule. He is either a finance guy or a scientist not too many do both.
The presentation did point out the Ligand royalty which is still helpful :-) (though I sold off a descent amount of my position).
Incidentally since the thread started with talking about some speculative Bio's one we started with ARWR has a small indirect tie to our discussion. Bruce Given their COO (or some upper management position) was the CEO of Encysive which developed Thelin. I bet if he gets the chance again he won't hire a sales force before the FDA decision :-).
Market Data 
Markets 
AI
